Literature DB >> 27796762

New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.

Isabel Heidegger1, Axel Heidenreich2, David Pfister2.   

Abstract

Prostate cancer is the most common cancer in men. In recent years, several new targeted therapeutic agents for the treatment of metastatic castration resistant prostate cancer (mCRPC) have been developed. These include androgen receptor targeting agents, new taxanes, radium-223, and immunotherapies. In this short review, we provide a summary of clinical and preclinical biomarkers for each of these new treatment strategies, also including new markers currently presented in conference papers only. Moreover, we address the role of these biomarkers in clinical routine with the aim to select best-personalized treatment strategies for patients. Finally, we provide a decision tree for selecting the proper therapy for patients with mCRPC according to the discussed biomarkers.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27796762     DOI： 10.1007/s11523-016-0461-6

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


  74 in total

1.  A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

Authors:  Douglas G McNeel; Thomas A Gardner; Celestia S Higano; Philip W Kantoff; Eric J Small; Mark H Wener; Robert B Sims; Todd DeVries; Nadeem A Sheikh; Robert Dreicer
Journal:  Cancer Immunol Res       Date:  2014-09-04       Impact factor: 11.151

2.  cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer.

Authors:  Alexandra Kienel; Daniel Porres; Axel Heidenreich; David Pfister
Journal:  J Urol       Date:  2015-04-18       Impact factor: 7.450

Review 3.  The androgen/androgen receptor axis in prostate cancer.

Authors:  Eric G Bluemn; Peter S Nelson
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

4.  Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Authors:  Chengfei Liu; Wei Lou; Yezi Zhu; Nagalakshmi Nadiminty; Chad T Schwartz; Christopher P Evans; Allen C Gao
Journal:  Clin Cancer Res       Date:  2014-04-16       Impact factor: 12.531

5.  Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.

Authors:  Neal D Shore; Simon Chowdhury; Arnauld Villers; Laurence Klotz; D Robert Siemens; Steve van Os; Nahla Hasabou; Fong Wang; Suman Bhattacharya; Axel Heidenreich
Journal:  Lancet Oncol       Date:  2016-01-14       Impact factor: 41.316

6.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

Authors:  Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis
Journal:  Eur Urol       Date:  2014-05-29       Impact factor: 20.096

7.  Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.

Authors:  Jean Hoffman-Censits; Wm Kevin Kelly
Journal:  Clin Cancer Res       Date:  2013-01-08       Impact factor: 12.531

8.  Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer.

Authors:  Hideyasu Matsuyama; Tomoyuki Shimabukuro; Isao Hara; Yasuo Kohjimoto; Kazuhiro Suzuki; Hidekazu Koike; Hirotsugu Uemura; Taiji Hayashi; Munehisa Ueno; Kiichiro Kodaira; Yoshihiko Tomita; Toshihiko Sakurai; Nobuaki Shimizu
Journal:  Int J Clin Oncol       Date:  2013-11-23       Impact factor: 3.402

9.  Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.

Authors:  Guanyi Zhang; Xichun Liu; Jianzhuo Li; Elisa Ledet; Xavier Alvarez; Yanfeng Qi; Xueqi Fu; Oliver Sartor; Yan Dong; Haitao Zhang
Journal:  Oncotarget       Date:  2015-09-15

10.  Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient.

Authors:  Marwan Ghosn; Alain Dagher; Fadi El-Karak
Journal:  J Biomed Res       Date:  2014-03-30
View more
  2 in total

1.  The Impact of Cand1 in Prostate Cancer.

Authors:  Andrea Eigentler; Piotr Tymoszuk; Johanna Zwick; Arndt A Schmitz; Andreas Pircher; Florian Kocher; Andreas Schlicker; Ralf Lesche; Georg Schäfer; Igor Theurl; Helmut Klocker; Isabel Heidegger
Journal:  Cancers (Basel)       Date:  2020-02-12       Impact factor: 6.639

2.  Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial.

Authors:  Isabel Heidegger; Renate Pichler; Axel Heidenreich; Wolfgang Horninger; Andreas Pircher
Journal:  Transl Androl Urol       Date:  2018-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.